

Intervet Inc.

Telefax Transmittal Cover sheet



P.O. Box 318 Millsboro, DE 19966 (302) 934-8051

FAX RECEIVED

MAY 07 sons

May 6, 2003

Intervet Inc.

405 Stat Street

GROUP 1600

OFFICIAL

5...pages including cover sheet.

PERSON TO:	COMPANY/DEPT TO:	FAX NUMBER:
<u> </u>		<u></u>

Examiner V. Portner

Group Art Unit

703 872 9307

PERSON FROM:	COMPANY/DEPT FROM:	FAX NUMBER:
4		
William D. Damer III		200 024 4205

William P. Ramey III

Intervet, Millsboro

302 934 4305

Patent Department

RE: USSN 09/544,683

Attorney Docket Number: 99471 US

Jacobs et al

Please accept the documents that follow in the above-identified application:

RCE Transmittal (1 page)

Request (3 pages)

Fee \$750.00

Cintervet

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN PROPRIETARY INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF YOU ARE NOT THE ADDRESSEE, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION, DISTRIBUTION, OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, NOTIFY US IMMEDIATELY BY TELEPHONE (COLLECT). THANK YOU.

PTO/SB/30 (01-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are requir

Request For Continued Examination (RCE) **Transmittal**

Intervet Inc.

Address to: Commissioner for Patents **Box RCE** Washington, DC 20231

BO NO 163 PORTO LO B COSECCIONI ON INIDITALE	audit uniess it contains a valid UNID control number.
Application Number	09/544,683
Filing Date	April 7, 2000
First Named Inventor	Jacobs et al
Art Unit	1645
Examiner Name	V. Portner
Attorney Docket Number	99471 US

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-Identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application fited prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. Submission required under 37 CFR 1.114				
a. Previously submitted				
i. Consider the amendment(s) reply under 37 CFR 1.116 previously filed on				
li. Consider the arguments in the Appeal Brief or Rely Brief previously filed on				
lii. Other				
Jb. Enclosed				
I. Amendment/Repty jij. Information Disclosure Statement (IDS)				
ii. Affidavit(s)/ Declaration(s) iv. Other				
2. Miscellaneous				
Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a				
a. pariod of moriths. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)				
b. Other				
3. Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filled.				
The Director is hereby authorized to charge the following fees or credit any overnayments to				
a. Deposit Account No. 02-2334				
i. RCE fee required under 37 CFR 1.17(e)				
ii. Extension of time fee (37 CFR 1.136 and 1.17)				
iii. Other				
b. Check in the amount of \$enclosed				
c. Payment by credit card (Form PTO-2038 enclosed)				
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED				

SIGNATURE OF APPLICANT, ATTOR	RNEY, OR AGENT REQUIRED
Name (Print/Type) William P. Ramey	Registration No. (Attornay/Agent) 44,295
Signature	Date 5/6/2003 🔀
CERTIFICATE OF MAILING	OR TRANSMISSION
I hereby certify that this correspondence is being deposited with the United States Pos- addressed to: Commissioner For Patents, Box Ree, Washington, DC 20231, or facsing shown below.	tal Service with sufficient postage as first class∰ail in an envelope tile transmitted to the U.S. Patent end Trademask Office on the date
Name (Print/Type) Katrina M Mears	
Signature VATALIA VIII CIL	Date 5/6/2003

Page I of 2

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to taxe 12 influence to complete, including gathering, preparing, and submitting the completed an placiation form to the USPTO. Time will vary depending upon the individual see. Ziny comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO BIS ABORRESS. SEND TO: Commissioner for Patents, Box RCE, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Received from < 934 4305 > at 5/6/03 4:26:18 PM [Eastern Daylight Time].

AMATA (NE)
25/A (NE)
25/A (NE)
25/A (NE)
25/A (NE)

Certificate of Facsimile Transmission

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:

Belgin | Mear

Atty Docket No.: I/99471 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JACOBS ET AL.

Serial No.: 09/544,683

Group Art Unit: 1645

Filed: April 7, 2000

Examiner: Portner, V.

For: CAMPYLOBACTER VACCINE

Assistant Commissioner of Patents Washington, D.C. 20231

Dear Sir:

REQUEST FOR CONTINUED EXAMINATION PURSUANT TO 37 CFR §132(B)

Applicants respectfully request continued examination of the above referenced application pursuant to 37 CFR §132(b). Prosecution on the above referenced application is closed, as the application is under a final rejection, dated February 6, 2003. Applicants are submitting the fee required pursuant to 37 CFR §1.17(e) and making the following submission. Please charge any required fees to deposit account number 02-2334.

I. Submission/Introduction

The application presently stands rejected from the final rejection of February 6, 2003. Applicants respectfully respond as follows: